If you are asking whether oral BPC-157 can be prescribed, the short answer is yes, but only in a narrow set of cases. Under an HHS enforcement discretion policy published in the Federal Register on October 30, 2026, oral BPC-157 acetate can be compounded for one identified patient on a valid prescription, by a state-licensed pharmacy, a federal facility or a licensed physician. That is enforcement discretion, not FDA approval. The policy does not reach capsules sold as supplements or products sold as research chemicals. Below you will find the conditions, what regulators and reviewers have said, the risks, the cost checks and a decision table.
Quick facts at a glance
| Fact | What the sources say |
|---|---|
| Check date | 2026-11-02 |
| Policy | HHS interim enforcement discretion policy on 503A compounding with certain peptides |
| Publication | Federal Register, October 30, 2026. LegitScript says HHS filed the notice on October 28, 2026. |
| Comments close | November 13, 2026 |
| Covered oral peptides | BPC-157 acetate and KPV acetate |
| Routes for BPC-157 acetate | Subcutaneous, intramuscular, oral, topical |
| Who may compound | State-licensed 503A pharmacy, federal facility or licensed physician |
| Ingredient rule | One active ingredient only |
| Not covered | 503B outsourcing facilities; products sold as research chemicals or dietary supplements |
| Permanence | Can be revised or withdrawn |
What is oral BPC-157, and what does the policy cover?
ABC News describes peptides as “strings of amino acids, smaller than a protein.” AP reports that BPC-157 is promoted to build muscle and recover from injuries. Those are the marketing claims that surround it, not findings from the policy.
The policy is HHS’s statement that it does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding BPC-157 acetate in the circumstances the policy lists. The full text is in the Federal Register notice, and the appendix naming the six peptides is on HHS’s appendix PDF.
The policy does not add BPC-157 to the final 503A bulks list. It does not reach 503B outsourcing facilities, and it does not reach products sold as research chemicals or dietary supplements. HHS says compounded drugs “are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed.”
The dates differ slightly by source. The Federal Register lists October 30, 2026 as the publication date, while LegitScript says HHS filed the notice on October 28, 2026. Comments close November 13, 2026.
Who may fit, and who should pause?
The policy is built around one situation: a prescription written for you as an identified patient, filled by a licensed compounder. Federal law allows compounding “for an identified individual patient based on the receipt of a valid prescription order,” and the compounder must be a licensed pharmacist in a State licensed pharmacy or Federal facility, or a licensed physician (federal compounding statute, 21 U.S.C. 353a).
You may fit this path if a licensed prescriber decides a compounded oral form is needed for you and a state-licensed pharmacy will make it under the conditions below. Your prescriber is also the person to ask whether a commercially available medicine would meet your needs.
Pause if any of these apply:
- You do not have a prescription written for you as an individual patient.
- The product is sold without a prescription, or as a capsule, supplement or research chemical.
- The product combines BPC-157 with another active ingredient, such as TB-500 or semaglutide.
- The source is a 503B outsourcing facility, which the policy excludes.
A PubMed Central review of compounding notes that the FDA does not allow compounding of a drug when the patient can be adequately and appropriately treated by an existing commercial product. That is a useful question to bring to your prescriber.
How does a prescription under the policy work?
LegitScript’s summary of the policy lists 10 conditions. In plain terms, the compounded product must:
- Contain a covered peptide ingredient in the specified form and route.
- Contain a single active pharmaceutical ingredient.
- Come from FDA-registered sourcing, with a valid certificate of analysis (COA) from a facility registered under section 510.
- Trace back to an original manufacturer that is FDA-registered and follows current good manufacturing practice, with its physical location printed on the COA. An intermediary must document the manufacturer’s qualification and the COA’s validation.
- Be reported to FDA and the relevant states for products compounded, serious adverse events and product quality issues.
- Carry the required label: “This is a compounded drug product. Not for resale.”
- Meet the patient-specific prescription requirement and avoid insanitary compounding.
LegitScript’s summary of the policy also covers the route rules in the table below.
Oral or injection: what changes
| Route | Covered for BPC-157 acetate | Extra condition the policy adds |
|---|---|---|
| Oral | Yes | Documentation that the specific formulation achieves adequate oral bioavailability in humans. An allowed oral route alone does not meet this condition. |
| Subcutaneous | Yes | Any delivery device packaged with or containing the drug must be an FDA 510(k)-cleared syringe. |
| Intramuscular | Yes | The same FDA 510(k)-cleared syringe rule applies. |
| Topical | Yes | The other policy conditions still apply. |
Oral is a listed route, but the pharmacy must hold documentation about the oral formulation itself. Injection routes carry the syringe rule. LegitScript notes that clearance of another device, such as an injector pen, does not satisfy the requirement.
What does the research say about BPC-157?
Most of what is in front of you is regulatory review, not trial results. The reports below are what the regulators and reviewers said.
What regulators and reviewers have said
FDA staff briefing materials, as reported by The Hill’s healthcare newsletter, concluded that “based on the available data, there is a lack of evidence to make a conclusion on the effectiveness of BPC-157 for treating [ulcerative colitis]” and that current information “weighs against” adding it to the 503A list. The same report says staff reached the same conclusion for all six peptides the committee approved.
In July 2026 the Pharmacy Compounding Advisory Committee narrowly voted to recommend adding BPC-157 and five other peptides to the compounding list. ABC News’s report on the July vote says the vote is non-binding and that six of the eight recently appointed members run clinics that offer peptides.
AP reported that most of the data on peptides comes from animal studies, in its report on the policy.
What the studies measured
The regulatory reports above do not name a human trial with a sample size or an effect size you can compare. For an oral product, the study that matters is the one behind the oral bioavailability documentation. Ask your prescriber or the pharmacy which human study that documentation relies on, and read it before you agree to a plan. Our peptides safety evidence (our research library) overview explains how these studies are usually read.
What the maker and sellers say
Sellers promote BPC-157 for muscle building and injury recovery, as AP reports. LegitScript lists the wording it treats as crossing into promotion: claims that a peptide “repairs” a specific condition, dosing recommendations for an unapproved drug, and statements that a substance is FDA-approved or legally permitted for compounding.
Our read
The policy answers who may legally compound and prescribe. Whether BPC-157 works for a given condition is a separate question, and it is worth asking about both.
Open questions to bring to your prescriber
- Which human study supports the oral bioavailability documentation for the specific product?
- What research does your prescriber rely on for your condition?
Safety, risks and side effects
FDA’s bulk substances risk page says compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration. It also notes complexities with peptide-related impurities and active pharmaceutical ingredient characterization. It adds that there are limited data in humans to inform safety-related considerations.
| Risk named | Who named it | What to ask about it |
|---|---|---|
| Immune reaction risk for certain routes; impurities and complex ingredient characterization | FDA bulk substances risk page | How the pharmacy characterizes the ingredient and its impurities |
| Contamination, allergic reactions and tumor growth | FDA, as reported by AP | The certificate of analysis for the batch |
| Ingredient described as untested and poorly defined | Partnership for Safe Medicines | The pharmacy’s state license for your state |
The Partnership for Safe Medicines filed a citizen petition on October 16, 2026 asking FDA not to allow compounding of six peptides, including BPC-157. It says it bought five vials of unapproved peptides from telehealth services in the past 45 days.
Under the policy, compounders must report serious adverse events and product quality issues to FDA and the relevant states. Whether oral BPC-157 fits your health history is the prescriber’s decision, made in the prescription step the policy requires.
What does oral BPC-157 cost?
Prices for compounded prescriptions change and vary by pharmacy and prescriber, so check today’s total cost directly with them before you agree to anything. Ask for the cost of each fill, how many fills one prescription covers, whether any consultation fees apply, and the renewal and refund terms in writing. Under the policy, each product must be prescribed for an identified patient, so ask whether a new prescription is needed for each order.
Is the seller legitimate, and how do you check?
Start with the pharmacy’s license. The Partnership for Safe Medicines reported that the vials it bought came from pharmacies licensed in Texas and Pennsylvania, and that none of those businesses had the appropriate licenses to dispense injectables in California. Licensing is set state by state.
Legal 500’s analysis of the policy says state boards generally oversee the day-to-day practice of state-licensed pharmacies. Check the board in your state.
Ask for the certificate of analysis and confirm the original manufacturer is FDA-registered and that its physical location is printed on the COA.
LegitScript updated its certification review effective November 2, 2026, and says certification does not guarantee advertising or payment access. Advertising platforms and payment providers set their own policies. A certified merchant still has no guarantee of those services.
ABC News reports that some advisory committee members who voted yes framed their support as a way to steer consumers away from an online black market where people buy these compounds from overseas sellers as unregulated “research chemicals,” with no doctor involved and no guarantee of what is in the vial.
What are the alternatives, including FDA-approved options and doing nothing?
An FDA-approved medicine for your condition is the option the policy leaves untouched. ABC News notes that some peptides, such as insulin and GLP-1s, are FDA-approved medicines. Ask your prescriber which approved options fit your situation and how they compare.
Doing nothing is also a choice. Talking it through with your prescriber first lets you make it deliberately.
Making it yourself is not covered. The policy names state-licensed pharmacies, federal facilities and licensed physicians as the compounders, and it excludes products sold as research chemicals.
If you are looking at oral supplements for general reasons, our oral health supplement safety guide covers who should be careful, and oral health supplements compared sets out price per day and refund terms. Those are different products from a prescribed compounded medication.
Decision table: when to take a closer look and when to pause
| Your situation | May be worth a closer look when | Pause or ask when |
|---|---|---|
| Prescription | A licensed physician or other licensed practitioner authorized by State law writes a prescription order for you as an identified patient | The offer does not include a prescription written for you as an identified patient |
| Pharmacy | A state-licensed pharmacy, federal facility or licensed physician will compound it | The source is a 503B outsourcing facility or sells research chemicals |
| Product form | Oral BPC-157 acetate as a single ingredient | It is combined with another peptide, or sold as a capsule or supplement |
| Oral documentation | The pharmacy can show documentation of oral bioavailability in humans for this formulation | The oral route is offered but no bioavailability documentation is given to you |
| Sourcing | The manufacturer is FDA-registered and its location is on the certificate of analysis | The manufacturer or its location cannot be named |
| Injection device (only if an injection route is used) | A syringe that is FDA 510(k)-cleared | An injector pen or auto-injector, since clearance of another device does not satisfy the policy |
| Marketing | Claims stay with what the maker says about the product | Claims that it repairs a specific condition, dosing advice, or implied FDA approval |
How to verify before you pay
- Confirm the prescription is written for you as an identified patient by a licensed prescriber.
- Ask the pharmacy for its state license and check it with your state board of pharmacy.
- Ask which product and route the prescription names, and confirm it is oral BPC-157 acetate as one ingredient.
- Ask for the bioavailability documentation for that oral formulation and which human study it relies on.
- Ask for the certificate of analysis, and confirm the original manufacturer is FDA-registered and its location is printed on it.
- If any injection is involved, confirm the device is an FDA 510(k)-cleared syringe.
- Get the total cost, number of fills, renewal terms and refund terms in writing.
Other questions people ask
Are BPC-157 pills legal?
Compounded oral BPC-157 acetate is covered by the policy only when every condition above is met. Capsules sold as supplements are not covered by the policy. Whether a product is lawful in your state is a question for your state board of pharmacy.
What is bioavailability documentation?
For an oral preparation, the policy requires documentation that the specific formulation achieves adequate oral bioavailability in humans. The pharmacy must have that documentation, and it is one of the questions to ask before you agree to a plan.
Does the policy treat oral and injection forms the same?
No. Both routes are listed for BPC-157 acetate. The oral route adds the bioavailability documentation requirement, and the injection routes add the FDA 510(k)-cleared syringe rule.
When could this change?
HHS’s appendix says it may revisit the policy, in whole or in part, if a safety signal or product quality issue arises. LegitScript says FDA may revise or withdraw the policy at any time. Formally adding peptides to the bulks list would require federal rulemaking, which AP reported could take years.
The timing is fluid. Comments on the policy close November 13, 2026, so check the Federal Register before you agree to any plan.
By SterlingMedicalCenter.org Editorial Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.